Late 2025 dropped a bomb in the pharma marketing world when Publicis Groupe snagged the entire global media account for Gilead Sciences. This was a major strategic play. It realigned Gilead’s whole approach, a company trying to manage a messy public health story while needing to clearly explain its science. The move showed they were serious about consolidating and innovating by ditching their old multi-agency model. That old setup, for all its different viewpoints, just couldn’t create the unified force needed for a global brand. So the big question on everyone’s mind was: how is Publicis actually going to pull this off and deliver one cohesive media strategy?
Key Takeaways
- Publicis’s late 2025 win consolidated all of Gilead’s media buying and planning, aiming for a consistent message and better efficiency across global markets.
- The strategy built a custom “Power of One” team, pulling specialists from agencies like Starcom and Digitas Health instead of just assigning the work to a single brand.
- A core part of the plan was using advanced programmatic buying, specifically RTB algorithms that could optimize ad spend using very precise health and demographic data.
- The whole point of this unified model is to cut down on media fragmentation, making sure Gilead’s scientific story lands clearly everywhere from the U.S. to new markets.
li>Running pharma media campaigns in 2026 means working through a minefield of regulations while still using data to personalize the content you’re delivering.
Gilead faced a bunch of challenges at once. As a biopharma company, their communications are a different beast. They’re doing complex scientific education and patient advocacy, all inside heavily regulated markets. Their previous setup, with different agencies running media in different regions, created inconsistent messaging and a horribly fragmented data picture. Trying to track a global campaign’s effectiveness when your data from North America, Europe, and APAC can’t talk to each other is an operational nightmare that kills any chance of getting real insights or making quick changes.
Publicis sold them on its “Power of One” philosophy, pitching a custom-built team that would pull the best people from across its network just for Gilead. The vision was to assemble a cross-functional unit, not just hand the account to a single agency like Starcom or Zenith. They tapped Sarah Jenkins, a media strategist with 20+ years in pharma, to lead the new global team. Her first task was massive: consolidate media planning and buying for a company active in over 35 countries, all while staying compliant with a maze of local rules. “The first three months were a deep dive into data architecture,” Jenkins said at a recent industry panel. “We needed to understand every single touchpoint, every audience segment, and critically, every regulatory nuance from Germany’s strict privacy laws to Japan’s unique advertising guidelines.”
The “Power of One” in Practice: Building the Integrated Team
Publicis’s winning strategy centered on integration. They didn’t just talk about a unified approach. they built a team for it. The roster included media planning and buying specialists from Starcom, digital strategy and engagement experts from Digitas Health, and data scientists from Epsilon to run the analytics. While the team’s physical hub was in Publicis’ London office, it really operated as a virtual unit, with key regional leads posted in markets like New York, Paris, and Singapore. This setup made sure local market knowledge didn’t get steamrolled by the push for global consistency.
Standardizing Gilead’s audience segmentation was an immediate priority. Before, different regions were using all kinds of different methods to define their target healthcare professionals (HCPs) and patient groups. The new Publicis team rolled out a global audience framework using aggregated, anonymized health data and behavioral insights. This framework which combined third-party data with Gilead’s own anonymized patient journey data, gave them a much more granular and consistent picture of who they were trying to reach. For example, they could go from targeting generic “oncologists” to identifying “oncologists specializing in solid tumor therapies practicing in urban academic medical centers in the Northeast U.S. with a high digital engagement score.” That’s the kind of granularity you need in pharma, where precise targeting is both efficient and often an ethical requirement.
Data-Driven Activation: Programmatic and Precision
Advanced programmatic capabilities drove the media strategy. Publicis plugged its proprietary Publicis Media Exchange (PMX) platform right into Gilead’s existing martech stack. This was about intelligent, real-time bidding (RTB) that optimized against specific campaign objectives, going way beyond just buying cheap impressions. Whether the goal was driving awareness among a specific group of HCPs or getting patients to approved education channels, the system was built for it. “We moved away from broad demographic targeting,” Jenkins noted. “Our programmatic buys were now informed by predictive analytics, identifying where our target audience was most likely to be receptive to a specific message, at a specific time.”
For instance, a campaign for a new inflammatory bowel disease treatment targeting gastroenterologists might buy impressions on medical journal sites, professional networks like Doximity, and even certain health news aggregators. All of it was dynamically adjusted based on performance metrics like click-throughs and content engagement. The key was the feedback loop: data from every impression and click fed back into the PMX platform to refine future bids and targeting. This kind of optimization is standard in CPG, but it’s way more complex in pharma because of the strict rules around data privacy and what you can claim. Publicis’s expertise with GDPR in Europe and HIPAA in the U.S. proved to be a huge advantage.
They also got creative with search and social. Pharma companies are usually timid with these channels, but Publicis argued for a more sophisticated, compliant way to engage. This meant creating targeted content strategies for platforms like LinkedIn to encourage peer-to-peer scientific discussion among HCPs. It also meant running carefully curated info campaigns on platforms like Pinterest for patient education, always linking back to approved, medically reviewed resources on Gilead’s own sites. The focus was always on providing value and information, not the kind of direct promotion that’s usually off-limits. “It’s about being where your audience is, and engaging thoughtfully within those spaces,” Jenkins emphasized. “For Gilead, that meant understanding the digital worlds of both clinicians and patients.”
Measuring Impact: Beyond Impressions
This media strategy’s success was measured by a framework that tied media spend to actual business outcomes, not just traditional metrics like reach or frequency. The team tracked things like how often HCPs engaged with scientific content, how many patients made it to disease education portals, and even (where permitted and anonymized) shifts in prescription patterns. They used advanced attribution models that looked past the last click to see the combined effect of all the media touchpoints. “Our mandate was to prove return on investment and deliver impressions,” Jenkins stated. “That meant building custom dashboards that integrated media data with sales data and anonymized patient data, all while following the strictest privacy rules.” An IAB report on 2025 digital ad revenue showed pharma spending on digital channels was up 18% globally, confirming the industry-wide move toward data-heavy strategies that Gilead and Publicis were now leading.
Global reporting was a monster of a challenge. Every market has different ways of collecting data, different regulatory reporting rules, and different ideas of what “success” even looks like. Publicis built a centralized data lake to pull in information from all the regional campaigns and standardize it. This gave Gilead’s global marketing team a real-time, consolidated view of their media performance. They could finally spot successful tactics to copy elsewhere and find underperforming areas that needed fixing, fast. This transparency and control was a world away from their old fragmented setup.
Here’s a perfect example of how it worked: they found that certain disease awareness campaigns, when run alongside specific HCP-targeted content on medical news sites, got a much higher engagement rate in Latin American markets than in North America. That single insight led them to reallocate their media budget, putting more money into those specific content and channel pairings in the regions where they worked best. Agile budget reallocation, driven by real-time data, is the sign of a media strategy that’s actually integrated.
The road for Publicis and Gilead wasn’t perfectly smooth. Integrating different systems and cultures across continents is a complex job, period. Regional teams, used to their old agency relationships, initially resisted. Overcoming that took constant communication, showing them the real-world benefits of the unified approach, and a ton of training on the new platforms. It took a lot of effort to get everyone on the same page, but the long-term payoff of a simple, data-driven global media presence was obvious. Speaking with one voice, backed by precise data, is invaluable for a company like Gilead with a mission built on complex science and global health. This kind of integrated, data-informed, and globally coordinated strategy is the future of pharmaceutical media.
The Publicis-Gilead partnership is a great case study of how a unified, data-driven media strategy can deliver real efficiencies and impact, even in a heavily regulated industry. By consolidating their operations and using advanced programmatic tools, Gilead found a clearer, more consistent global voice, which in the end helps both patients and the scientific community.
What does “Power of One” mean in the context of Publicis’ strategy?
The “Power of One” is Publicis Groupe’s model for building custom, integrated teams for a single client. They pull talent from their different agency brands (like Starcom, Digitas Health, Epsilon) to create a unified strategy and avoid the usual agency silos.
How did Publicis address the challenge of regulatory compliance in pharmaceutical media?
They embedded regulatory experts directly into the media team and built a global audience framework that complied with strict privacy laws like GDPR and HIPAA. Their programmatic buying platforms were specifically configured to work within local advertising rules, making sure all communications were compliant everywhere.
What role did programmatic advertising play in Gilead’s new media strategy?
Programmatic advertising, run through the Publicis Media Exchange (PMX), was the engine of the strategy. It allowed for real-time bidding and ad optimization to target very specific HCP and patient groups based on predictive analytics, which made their ad spend much more efficient and effective for delivering complex medical messages.
How was the success of the media strategy measured beyond traditional metrics?
Success was measured with a framework that connected media spend to business results. They tracked metrics like HCP engagement with scientific content, patient traffic to education websites, and even shifts in anonymized prescription data. Advanced attribution models helped them see the total impact of all media touchpoints.
What was the primary benefit of consolidating Gilead’s global media account under one agency network?
The biggest benefit was getting more efficiency and consistency, giving Gilead a single, clear voice for its scientific communications worldwide. The consolidation cut down on media fragmentation, made data analysis much simpler, and let them shift budget quickly based on real-time performance across all their markets.
